Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Reuters

07 May 2020 0 shares 1 views

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Reuters

Published 07 May 2020

Japan has approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country's first officially authorised drug for the disease.

Full Article

European, South Korean authorities vie for COVID-19 antiviral remdesivir

Reuters 29 May 2020

European and South Korean authorities are vying for Gilead Sciences' potential COVID-19 treatment, remdesivir, even though the..

EU regulator promises speedy review of potential COVID-19 drug remdesivir
Reuters 29 May 2020
South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge
Reuters 29 May 2020
South Korea seeks to import anti-viral remdesivir as new virus cases emerge
Reuters 29 May 2020
Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial
Reuters 28 May 2020

More coverage

Roche to study remdesivir/Actemra cocktail against severe COVID-19 pneumonia

Reuters 28 May 2020

Swiss drugmaker Roche said on Thursday it would study its anti-inflammation drug Actemra mixed with Gilead Sciences Inc's..

Gilead study shows shorter five-day course of remdesivir works as well as 10-day one
Reuters 27 May 2020
Britain to provide anti-viral drug remdesivir to some COVID-19 patients
Reuters 26 May 2020
NIH trial: Gilead's drug works best in COVID patients on oxygen
Reuters 23 May 2020
Peer-reviewed data shows Gilead's drug helps COVID-19 recovery time
Reuters 23 May 2020

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

You might like

Related news coverage

European, South Korean authorities vie for COVID-19 antiviral remdesivir

Advertisement

More coverage

Roche to study remdesivir/Actemra cocktail against severe COVID-19 pneumonia